These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 24301955)
21. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia. Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812 [TBL] [Abstract][Full Text] [Related]
22. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174 [TBL] [Abstract][Full Text] [Related]
23. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes. Liu X; Zhang G; Yi Y; Xiao L; Pei M; Liu S; Luo Y; Zhong H; Xu Y; Zheng W; Shen J Leuk Lymphoma; 2013 Nov; 54(11):2466-73. PubMed ID: 23432690 [TBL] [Abstract][Full Text] [Related]
24. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine. Voso MT; Fabiani E; Piciocchi A; Matteucci C; Brandimarte L; Finelli C; Pogliani E; Angelucci E; Fioritoni G; Musto P; Greco M; Criscuolo M; Fianchi L; Vignetti M; Santini V; Hohaus S; Mecucci C; Leone G Leukemia; 2011 Dec; 25(12):1910-3. PubMed ID: 21760590 [No Abstract] [Full Text] [Related]
25. [Mutations in TET2 in myeloid cancers]. Bernard OA; Delhommeau F; Fontenay M; Vainchenker W Med Sci (Paris); 2009 Oct; 25(10):785-8. PubMed ID: 19849974 [No Abstract] [Full Text] [Related]
27. Mutation in TET2 in myeloid cancers. Tefferi A; Lim KH; Levine R N Engl J Med; 2009 Sep; 361(11):1117; author reply 1117-8. PubMed ID: 19741235 [No Abstract] [Full Text] [Related]
28. Down-regulation of TET2 in CD3⁺ and CD34⁺ cells of myelodysplastic syndromes and enhances CD34⁺ cells proliferation. Zhang W; Shao Z; Fu R; Wang H; Li L; Liu H Int J Clin Exp Pathol; 2015; 8(9):10840-6. PubMed ID: 26617797 [TBL] [Abstract][Full Text] [Related]
29. [TET2 and DLK1 gene expression and their clinical significance in bone marrow CD(3)(+) T cells of patients with myelodysplastic syndrome]. Zhang W; Fu R; Wang HQ; Li LJ; Yue LZ; Liu H; Qu W; Liang Y; Wang GJ; Wang XM; Wu YH; Liu H; Song J; Guan J; Xing LM; Shao ZH Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):543-6. PubMed ID: 22943828 [TBL] [Abstract][Full Text] [Related]
30. Necrotizing myopathy associated with TET2-mutated myelodysplastic syndrome. Dietrich T; de Mornac D; Garnier A; Espitia A; Néel A; Normand A; Toquet C; Agard C QJM; 2022 Sep; 115(9):633-634. PubMed ID: 35689623 [No Abstract] [Full Text] [Related]
31. Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. Pollyea DA; Raval A; Kusler B; Gotlib JR; Alizadeh AA; Mitchell BS Hematol Oncol; 2011 Sep; 29(3):157-60. PubMed ID: 21922510 [No Abstract] [Full Text] [Related]
32. TET2 rs2454206, TET2 rs12498609 and ASXL1 rs3746609 single nucleotide polymorphisms in patients with myelodysplastic syndromes. Hu J; Xu J; Tian T; Xie J; Fan L; Zhu G; Xia T; Chen X; Tan Y; Chen X; Ren F; Zhang Y; Wang H; Xu Z Blood Cells Mol Dis; 2019 Feb; 74():44-50. PubMed ID: 30454965 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases. Klaus M; Psaraki A; Mastrodemou S; Pyrovolaki K; Mavroudi I; Kalpadakis C; Papadaki HA Leuk Res; 2011 Mar; 35(3):413-5. PubMed ID: 21087791 [TBL] [Abstract][Full Text] [Related]
35. Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation. Kim M; Yahng SA; Kwon A; Park J; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Lee JW; Min WS; Lee SH; Kim YJ Bone Marrow Transplant; 2015 Aug; 50(8):1132-4. PubMed ID: 25961778 [No Abstract] [Full Text] [Related]
36. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome. Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924 [TBL] [Abstract][Full Text] [Related]
37. Acute myeloid leukaemia: recent data on prognostic gene mutations, in relation to stratified therapies for elderly patients. Soura EN; Karikas GA J BUON; 2019; 24(4):1326-1339. PubMed ID: 31646775 [TBL] [Abstract][Full Text] [Related]
38. Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy? Lee EJ; Zeidan AM Expert Rev Hematol; 2015 Apr; 8(2):155-8. PubMed ID: 25697572 [TBL] [Abstract][Full Text] [Related]
39. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932 [TBL] [Abstract][Full Text] [Related]
40. Myelodysplastic syndrome with extramedullary erythroid hyperplasia induced by loss of Tet2 in mice. Muto T; Sashida G; Hasegawa N; Nakaseko C; Yokote K; Shimoda K; Iwama A Leuk Lymphoma; 2015 Feb; 56(2):520-3. PubMed ID: 24844363 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]